# A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT07452198** · PHASE3 · RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 358 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** GR1803 injection
- **DRUG:** Daratumumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07452198
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2029-03
- **Final completion:** 2030-03
- **Target enrollment:** 358 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07452198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07452198, "A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07452198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*